Bio-Techne is a biotechnology business based in the US. Bio-Techne shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $63.82 – a decrease of 3.08% over the previous week. Bio-Techne employs 3,100 staff and has a trailing 12-month revenue of around $1.2 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Bio-Techne stock price (NASDAQ: TECH)
Use our graph to track the performance of TECH stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Bio-Techne stock undervalued or overvalued?
Valuing Bio-Techne stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Techne's P/E ratio
Bio-Techne's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 132x. In other words, Bio-Techne shares trade at around 132x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Bio-Techne's PEG ratio
Bio-Techne's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8902. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Techne's EBITDA
Bio-Techne's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $318.5 million.
The EBITDA is a measure of a Bio-Techne's overall financial performance and is widely used to measure a its profitability.
Bio-Techne financials
Revenue TTM
$1.2 billion
Operating margin TTM
14.51%
Gross profit TTM
$813.2 million
Return on assets TTM
6.09%
Return on equity TTM
3.8%
Profit margin
6.41%
Book value
$12.62
Market Capitalization
$10.1 billion
TTM: trailing 12 months
Bio-Techne share dividends
Dividend payout ratio: 16.58% of net profits
Recently Bio-Techne has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Bio-Techne's case, that would currently equate to about $0.32 per share.
While Bio-Techne's payout ratio might seem low, this can signify that Bio-Techne is investing more in its future growth.
Bio-Techne's most recent dividend payout was on 27 November 2025. The latest dividend was paid out to all shareholders who bought their shares by 16 November 2025 (the "ex-dividend date").
Have Bio-Techne's shares ever split?
Bio-Techne's shares were
split on a 4:1 basis on 29 November 2022
. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Bio-Techne shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Bio-Techne shares which in turn could have impacted Bio-Techne's share price.
Bio-Techne share price volatility
Over the last 12 months, Bio-Techne's shares have ranged in value from as little as $45.8048 up to $78.8318. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne's is 1.467. This would suggest that Bio-Techne's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bio-Techne overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Frequently asked questions
null What percentage of Bio-Techne is owned by insiders or institutions? Currently 0.282% of Bio-Techne shares are held by insiders and 106.901% by institutions.How many people work for Bio-Techne? Latest data suggests 3,100 work at Bio-Techne.When does the fiscal year end for Bio-Techne? Bio-Techne's fiscal year ends in June.Where is Bio-Techne based? Bio-Techne's address is: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413What is Bio-Techne's ISIN number? Bio-Techne's international securities identification number is: US09073M1045What is Bio-Techne's CUSIP number? Bio-Techne's Committee on Uniform Securities Identification Procedures number is: 878377100
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
